Literature DB >> 12052696

Investigation of polymeric nanoparticles as carriers of enalaprilat for oral administration.

P Ahlin1, J Kristl, A Kristl, F Vrecer.   

Abstract

Enalaprilat is a typical angiotensin-converting enzyme inhibitor and is very poorly absorbed from the gastrointestinal tract. The aim of this study was to design and characterize poly-(lactide-co-glycolide) (PLGA) and polymethylmethacrylate (PMMA) nanoparticles containing enalaprilat and to evaluate the potential of these colloidal carriers for the transport of drugs through the intestinal mucosa. Nanoparticle dispersions were prepared by the emulsification-diffusion method and characterized according to particle size, zeta potential, entrapment efficiency and physical stability. Effective permeabilities through rat jejunum of enalaprilat in solution and in enalaprilat-loaded nanoparticles were compared using side-by-side diffusion chambers. The solubility of enalaprilat is very low in many acceptable organic solvents, but in benzyl alcohol is sufficient to enable the production of nanoparticles by the emulsification-diffusion process. The diameters of drug-loaded PMMA and PLGA nanoparticles were 297 and 204 nm, respectively. The concentration of the stabilizer polyvinyl alcohol (PVA) in dispersion has an influence on particle size but not on drug entrapment. The type of polymer has a decisive influence on drug content--7 and 13% for PMMA and PLGA nanoparticles, respectively. In vitro release studies show a biphasic release of enalaprilat from nanoparticle dispersions-fast in the first step and very slow in the second. The apparent permeability coefficient across rat jejunum of enalaprilat entrapped in PLGA nanoparticles is not significantly improved compared with enalaprilat in solution.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12052696     DOI: 10.1016/s0378-5173(02)00076-5

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  20 in total

1.  Modified nanoprecipitation method for preparation of cytarabine-loaded PLGA nanoparticles.

Authors:  Khushwant S Yadav; Krutika K Sawant
Journal:  AAPS PharmSciTech       Date:  2010-09-15       Impact factor: 3.246

Review 2.  Drug transport to brain with targeted nanoparticles.

Authors:  Jean-Christophe Olivier
Journal:  NeuroRx       Date:  2005-01

3.  Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery.

Authors:  Huanyu Dou; Christopher J Destache; Justin R Morehead; R Lee Mosley; Michael D Boska; Jeffrey Kingsley; Santhi Gorantla; Larisa Poluektova; Jay A Nelson; Mahesh Chaubal; Jane Werling; James Kipp; Barrett E Rabinow; Howard E Gendelman
Journal:  Blood       Date:  2006-06-29       Impact factor: 22.113

4.  Investigation on magnetically controlled delivery of doxorubicin from superparamagnetic nanocarriers of gelatin crosslinked with genipin.

Authors:  Jyoti Choubey; A K Bajpai
Journal:  J Mater Sci Mater Med       Date:  2010-02-05       Impact factor: 3.896

5.  Effects of particle size and surface modification on cellular uptake and biodistribution of polymeric nanoparticles for drug delivery.

Authors:  Sneha A Kulkarni; Si-Shen Feng
Journal:  Pharm Res       Date:  2013-01-12       Impact factor: 4.200

6.  Core-shell nanoparticulate formulation of gemcitabine: lyophilization, stability studies, and in vivo evaluation.

Authors:  Deepak Chitkara; Anupama Mittal; Ram I Mahato; Neeraj Kumar
Journal:  Drug Deliv Transl Res       Date:  2014-12       Impact factor: 4.617

7.  Design of vancomycin RS-100 nanoparticles in order to increase the intestinal permeability.

Authors:  Badir Delf Loveymi; Mitra Jelvehgari; Parvin Zakeri-Milani; Hadi Valizadeh
Journal:  Adv Pharm Bull       Date:  2012-02-15

8.  Transanal delivery of angiotensin converting enzyme inhibitor prevents colonic fibrosis in a mouse colitis model: development of a unique mode of treatment.

Authors:  Hiroyuki Koga; Hua Yang; Jeremy Adler; Ellen M Zimmermann; Daniel H Teitelbaum
Journal:  Surgery       Date:  2008-08       Impact factor: 3.982

9.  Angiotensin converting enzyme-inhibitor reduces colitis severity in an IL-10 knockout model.

Authors:  Ryo Sueyoshi; Kathleen M Woods Ignatoski; Stephanie Daignault; Manabu Okawada; Daniel H Teitelbaum
Journal:  Dig Dis Sci       Date:  2013-08-15       Impact factor: 3.199

10.  Cannabinoid derivate-loaded PLGA nanocarriers for oral administration: formulation, characterization, and cytotoxicity studies.

Authors:  Lucía Martín-Banderas; Josefa Alvarez-Fuentes; Matilde Durán-Lobato; José Prados; Consolación Melguizo; Mercedes Fernández-Arévalo; Maria Ángeles Holgado
Journal:  Int J Nanomedicine       Date:  2012-11-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.